GnRH-Agonisten in der Kleintierpraxis – Was wissen wir 13 Jahre nach der EU-Zulassung?

Stempel, Sabrina; Goericke-Pesch, Sandra

doi:10.1055/a-1274-9268

Cited by 4 publications

(1 citation statement)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite GnRH agonist SRIs containing buserelin [17,18], azagly nafarelin [5,12,14] and deslorelin [8][9][10][11]19] had been studied for non-surgical suppression of male canine reproductive function, only SRIs containing deslorelin are currently marketed in Europe [20]. Nevertheless, GnRH-agonist SRIs are a huge market and more and more pet owners are abandoning surgery in favor of GnRH agonist SRI application.…”

Section: Introductionmentioning

confidence: 99%

The use of a 4.7 mg deslorelin slow release implant in male dogs in the field

Vasetska,

Körber,

Pilgram

et al. 2023

Tierarztl Prax Ausg K Kleintiere Heimtiere

Self Cite

View full text Add to dashboard Cite

Objective Slow-release GnRH agonist implants (SRI) are used for reversible medical downregulation of testicular function in male dogs as an alternative to surgery. The 4.7 mg deslorelin SRI should reduce testosterone after 6–8 weeks and induce castration-like effects for 6 months (mon). However, some individual variation is described in the field in regard to onset and duration of effect. For this reason, we aimed to study the effects of the 4.7 mg deslorelin SRI in a larger cohort. Material and methods In total 50 intact, healthy male dogs (12–48 months, mon; 9–40 kg) were treated with a 4.7 mg deslorelin SRI into the umbilical area (TG, n=45) or served as untreated controls (CG, n=5). CG dogs were surgically castrated after measurement of testicular dimensions and blood sampling for testosterone. In TG, SRIs remained for 5 mon in place and subsequently 3–7 male dogs were surgically castrated at removal (week, W 0) or 1, 2, 3, 4, 5, 6, 7, 8 or 10 weeks later. Examination parameters were testicular dimensions (before treatment, at 4, 8, 12 W, 5 mon, weekly until castration), testosterone (before treatment, at 8 W, 5 mon, castration) and testicular histology (castration). Results Whereas examination parameters did not differ between CG and TG before treatment, testicular volume and testosterone was significantly reduced at all time points during treatment. In all but 3 (8 W) and 2 male dogs (5 mon) testosterone was basal during treatment before removal, whereas the parameters were significantly reduced compared to pre-treatment in the respective dogs. After implant removal, testosterone and testicular volumes increased. However, different to earlier studies, the „restart“ was more variable with individual basal testosterone until W7, but also physiological testosterone concentrations in W2. Similarly, histological testicular findings at castration were quite variable: besides an arrest on spermatogonia and spermatocytes, elongated spermatids with normal spermatogenesis were found in individual dogs. Conclusion Our study confirms the efficacy of the deslorelin SRI, but also individual variation especially regarding reversibility of effects on endocrine and germinative testicular function. Clinical relevance Deslorelin SRIs offer a suitable alternative to surgical castration with individual variation to be considered when used in clinical practice.

show abstract

Section: Introductionmentioning

confidence: 99%

The use of a 4.7 mg deslorelin slow release implant in male dogs in the field

Vasetska,

Körber,

Pilgram

et al. 2023

Tierarztl Prax Ausg K Kleintiere Heimtiere

Self Cite

View full text Add to dashboard Cite

show abstract

Clinical Approach to Infertility

Goericke-Pesch¹

2022

Feline Reproduction

View full text Add to dashboard Cite

What Happens in Male Dogs after Treatment with a 4.7 mg Deslorelin Implant? I. Flare up and Downregulation

Stempel

Körber

Reifarth

et al. 2022

Animals

Self Cite

View full text Add to dashboard Cite

Although registered since 2007, knowledge about changes in testosterone concentrations (T), testicular and prostatic volumes (TV, PV) and semen quality, as well as the time point of infertility following treatment with a 4.7 mg deslorelin (DES) slow-release implant, is limited. Therefore, seven sexually mature male dogs were treated with DES (TG); three male dogs treated with saline served as controls (CG). The study assessed local tolerance, TV, PV, semen parameters and T subsequent to GnRH/hCG stimulation in regular intervals. Local tolerance was good. In TG, T was increased right after treatment, but decreased four hours afterwards. Subsequently, TV, PV, semen quality and T decreased over time in TG, but not CG. T was basal (≤0.1 ng/mL) from D28 onwards. Response to GnRH/hCG stimulation was variable, with two TG dogs having increased T post-stimulation on all study days independent of pre-treatment concentrations. A(zoo)spermia in TG was observed from D35–D77 in all seven dogs. Whereas treatment was still effective in six TG dogs five months after implant insertion, it was fully reversed in one dog in terms of T and spermatozoa on the last examination. These results indicate high variation in individual dogs, necessary to consider when advising dog owners.

show abstract

GnRH-Agonisten in der Kleintierpraxis – Was wissen wir 13 Jahre nach der EU-Zulassung?

Cited by 4 publications

References 81 publications

The use of a 4.7 mg deslorelin slow release implant in male dogs in the field

The use of a 4.7 mg deslorelin slow release implant in male dogs in the field

Clinical Approach to Infertility

What Happens in Male Dogs after Treatment with a 4.7 mg Deslorelin Implant? I. Flare up and Downregulation

Contact Info

Product

Resources

About